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Introduction {#sec1}
============

Tel1^ATM^ and Mec1^ATR^ mediate DNA damage checkpoints ([@bib30]) by activating the Chk1^CHK1^ and Rad53^CHK2^ kinases, which transduce the signal to downstream targets. Rad53 controls replication fork integrity and phosphorylates Dun1 to upregulate deoxy-nucleotide triphosphate (dNTP) levels ([@bib6], [@bib77]). Checkpoint deactivation occurs during recovery or adaptation and is mediated by the PP1, PP2C, and PP4 phosphatases ([@bib7], [@bib40], [@bib51], [@bib62]). Hydroxyurea (HU) inhibits replication by limiting dNTPs, causing replication stress and Mec1 activation ([@bib75], [@bib80]).

PP2A and PP2A-like Ser/Thr phosphatases are ceramide-activated protein phosphatases (CAPPs) ([@bib38], [@bib39], [@bib61]). *PPH21* and *PPH22* encode PP2A catalytic subunits, whereas Tpd3 is a scaffolding subunit. The Cdc55 and Rts1 regulatory subunits are mutually exclusive and direct PP2As to distinct processes. The Ppm1 methyltransferase methylates and activates PP2A. Sit4 is a PP2A-like phosphatase that interacts with four activators known as Sit4-associating proteins (Saps). Pph21/Pph22 and Sit4 interact with Tap42, a target of TOR complex 1 (TORC1) ([@bib17]). Rrd2 and Rrd1 are PP2A- and PP2A-like activators. Tip41 inhibits Tap42, and their interaction is influenced by Ptc1 phosphatase. The PP2A/PP2A-like signaling pathways are not fully characterized ([@bib19]). According to the model, TORC1 phosphorylates Tap42, which inhibits PP2As; PP2A dephosphorylates TORC1 effectors ([@bib52]). Gln3, Npr1, Nnk1, and Rtg3 are PP2A targets involved in nitrogen and amino acid metabolism ([@bib34]). PP2A influences the ataxia telangiectasia mutated (ATM)-dependent DNA damage response (DDR) ([@bib23]).

We show that Irc21, a cytochrome b~5~-like enzyme influencing genome stability ([@bib2], [@bib24], [@bib28], [@bib50]) activates PP2A by promoting the synthesis of dihydroceramide (DHC) and that PP2A is a central hub in a regulatory loop that couples three metabolic pathways dependent on Irc21, Ppm1 and TORC1, with the ataxia telangiectasia and Rad3-related (ATR)-mediated DDR.

Results {#sec2}
=======

Irc21 Influences the Replication Stress Response {#sec2.1}
------------------------------------------------

We identified *irc21Δ* as suppressor of the HU sensitivity of the dominant-negative *rad53-D339A* and the kinase-deficient *rad53-K227A* mutations ([@bib8], [@bib21]). The suppression was validated in the W303 ([@bib83]) background ([Figures 1](#fig1){ref-type="fig"}A and 1B). *irc21Δ* also rescued the HU sensitivity of the *mec1Δ sml1Δ*, *rad53Δ sml1Δ*, *mec1Δ rad53Δ sml1Δ*, and *chk1Δ rad53Δ sml1Δ* strains ([Figure 1](#fig1){ref-type="fig"}C). Sml1 inhibits ribonucleotide reductase and its ablation bypasses the essential functions of *MEC1* and *RAD53* by increasing dNTP levels ([@bib16], [@bib32], [@bib94]). *IRC21* and *SML1* double ablation caused an additive suppression in a *rad53-K227A* background ([Figure S1](#mmc1){ref-type="supplementary-material"}A), and *irc21Δ* mutants were hypersensitive to high HU doses ([Figure S1](#mmc1){ref-type="supplementary-material"}B), suggesting that *irc21Δ* suppression does not depend on dNTP levels or intrinsic HU resistance.Figure 1*IRC21* Deletion Rescues Checkpoint Mutants(A) Cells were grown on synthetic-defined (SD/-Ura) plates with glucose 2% or galactose 2% ± hydroxyurea (HU).(B and C) Cells were grown on YPD plates with or without 5 mM HU (B) or 2 mM HU (C).(D) *sml1Δ*, *sml1Δ mec1Δ*, *sml1Δ irc21Δ*, and *sml1Δ mec1Δ irc21Δ* cells were arrested in G~1~ with α-factor (alpha) and released into YPD containing 0.2 M HU. After 3 hr, cells were released into YPD. Samples were collected at the indicated times to detect Rad53 by western blot analysis.(E) Cells were arrested with α-factor and released in YPD with or without 0.2 M HU. Cells were treated for 3 hr, and samples were collected to detect Rad53 and Mre11.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We addressed whether *IRC21* deletion influenced the Mec1-dependent Rad53 phosphorylation and dephosphorylation ([@bib22], [@bib74]) during checkpoint activation and deactivation ([Figure 1](#fig1){ref-type="fig"}D). *sml1Δ*, *mec1Δ sml1Δ*, *irc21Δ sml1Δ*, and *mec1Δ irc21Δ sml1Δ* mutants were released from G~1~ into HU to activate Mec1 and released into medium without HU to recover ([@bib65]). In *sml1Δ* cells, Rad53 phosphorylation was obvious in HU and decreased during recovery. Rad53 phosphorylation was nearly abolished in *mec1Δ sml1Δ* mutants. *IRC21* deletion restored Rad53 phosphorylation in *mec1Δ sml1Δ* cells and also delayed Rad53 dephosphorylation in *sml1Δ* mutants. The persistence of Rad53 phosphorylation in *mec1Δ irc21Δ sml1Δ* mutants recovering from HU correlated with the inability to efficiently complete S phase ([Figure S1](#mmc1){ref-type="supplementary-material"}C). We addressed whether *irc21Δ*-mediated rescue of Rad53 phosphorylation in *mec1Δ* cells was dependent on Tel1, which phosphorylates Mre11 and shares overlapping functions with Mec1 ([@bib89]). Rad53 was not phosphorylated in *mec1Δ tel1Δ irc21Δ sml1Δ* cells exposed to HU ([Figure 1](#fig1){ref-type="fig"}E), suggesting that the *irc21Δ*-mediated rescue of Rad53 phosphorylation in *mec1Δ* cells depends on Tel1. The *irc21Δ* suppression mechanism was not due to Tel1 hyperactivation because *IRC21* deletion did not further elevate Tel1-dependent Mre11 phosphorylation ([@bib37]; [Figure 1](#fig1){ref-type="fig"}E).

*irc21Δ* did not rescue the HU sensitivity of *dun1Δ* mutants ([Figure S1](#mmc1){ref-type="supplementary-material"}D), further suggesting that Irc21 does not cause an increase in dNTP pools. Moreover, *IRC21* deletion failed to fully phosphorylate Dun1 in *mec1* or *rad53* mutants ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Hence, the Tel1-mediated Rad53 phosphorylation in *sml1Δ mec1Δ* mutants is somewhat suboptimal because it prevents Rad53 from phosphorylating Dun1. This is consistent with the notion that certain phospho-isoforms of Rad53 are unable to phosphorylate Dun1 ([@bib49]). *irc21Δ* mutants failed to efficiently recover from the HU treatment, as visualized by the fluorescence-activated cell sorting (FACS) profile and by the delayed dephosphorylation of Rad53 and Dun1 ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

Irc21 Affects Mitochondrial Functions and Lipid Biosynthesis {#sec2.2}
------------------------------------------------------------

Irc21 contains an NADH-cytochrome b~5~ reductase domain (CBR); CBRs are involved in mitochondrial functions and lipid biosynthesis ([Figure 2](#fig2){ref-type="fig"}A). We measured the oxygen consumption rate of logarithmically growing cells and found that *irc21Δ* mutants showed a higher respiration rate compared with wild-type (WT) cells ([Figure 2](#fig2){ref-type="fig"}B). During respiration, mitochondria generate reactive oxygen species (ROS). Using the oxidant-sensing probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) to measure ROS levels ([@bib15]), we found that exponentially growing *irc21Δ* cells accumulated more ROS than WT cells ([Figure 2](#fig2){ref-type="fig"}C), as shown previously ([@bib60]). Consistent with higher respiration activity, *irc21Δ* cells were hypersensitive to paraquat (1,1′-dimethyl-4,4'-bipyridinium dichloride), a redox cycler that stimulates respiration-dependent superoxide production ([@bib12]; [Figure 2](#fig2){ref-type="fig"}D). This did not reflect general ROS sensitivity because *irc21Δ* cells were resistant to *tert*-butyl hydroperoxide (t-BOOH), which produces ROS and damages a variety of cellular constituents, including lipids ([@bib25]; [Figure 2](#fig2){ref-type="fig"}D). In agreement with putative Irc21 CBR activity, *irc21Δ* cells were resistant to mersalyl, a mercurial diuretic that affects mitochondrial functions and inhibits the NADH-cytochrome b~5~ reductase ([@bib9]; [Figure 2](#fig2){ref-type="fig"}D). The cytochrome b~5~-dependent electron transport system is also involved in lipid metabolic processes such as cholesterol/ergosterol biosynthesis and desaturation and elongation of fatty acids ([@bib91]). In particular, heme is required for the enzymatic activities of Erg3p (sterol C5-6 desaturase), Erg5p (sterol C22--23 desaturase), and Erg11p (sterol 14α-demethylase). We analyzed the sensitivity of *irc21Δ* cells to inhibition of Cyb5-dependent Erg11 by fluconazole and Cyb5-independent Erg1 (squalene epoxidase) by terbinafine ([@bib44], [@bib46], [@bib66]; [Figure 2](#fig2){ref-type="fig"}D). *irc21Δ* cells were specifically sensitive to fluconazole and not to terbinafine, suggesting that *IRC21* ablation exacerbates the inhibitory effect of fluconazole on ergosterol synthesis. Fatty acid metabolism involves Cytb5-dependent reactions. We tested whether *irc21Δ* cells were sensitive to overall dampening of fatty acid production by cerulenin, an inhibitor of fatty acid synthase (FAS) that prevents the synthesis of medium- and long-chain fatty acids (MCFAs and LCFAs, respectively) and of very-LCFAs (VLCFAs) ([@bib4]). *irc21* mutants were hypersensitive to cerulenin ([Figure 2](#fig2){ref-type="fig"}D), implying that Irc21 may affect fatty acid metabolism. Taken together, the sensitivity/resistance profile suggests that Irc21 influences CBR-dependent processes.Figure 2*IRC21* Deletion Impairs Cytb5-Dependent Processes(A) Classification of putative Irc21 processes based on the gene ontology PANTHER (protein analysis through evolutionary relationships) classification system.(B) Oxygen consumption rate of exponentially growing WT and *irc21Δ* cells. The results are shown as means ± SD of triplicates. ^∗∗∗∗^p \< 0.0001.(C) Determination of ROS levels using the DCFH-DA assay in WT and *irc21Δ* cells depending on the incubation period. The results are shown as means ± SD of triplicates. p values are indicated.(D) Spot assay of WT and *irc21Δ* cells on YPD plates with or without paraquat, mersalyl, t-BOOH, terbinafine, fluconazole, or cerulenin at the indicated concentrations. Drug mechanisms of action are illustrated.

*irc21Δ* and PP2A Mutants Genetically Interact and Exhibit Similar Interactome Profiles {#sec2.3}
---------------------------------------------------------------------------------------

We compared the *irc21Δ* genetic interaction signatures with those of 3,884 other deletion strains ([@bib14]) by calculating correlation scores (R) based on genetic interactions with 1,712 mutants. Among the top ten array strains with synthetic genetic array (SGA) interactomes most similar to *irc21Δ* mutants, we identified deletions in the *RRD1* (R = 0.39), *TIP41* (R = 0.33), *SAP185* (R = 0.19), and *RRD2* (R = 0.17) genes ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A), which encode PP2A and PP2A-like regulators ([@bib54], [@bib90]; [Figure 3](#fig3){ref-type="fig"}E). The interactome correlation between *irc21Δ* and *rrd1Δ* was quantitatively similar to the one between the two PP2A/PP2A-like activators *rrd1Δ* and *tip41*Δ (R = 0.37). The second hit with an *irc21Δ* interactome correlation similar to *rrd1*Δ was *imp2′Δ* (R = 0.38) ([Figure S2](#mmc1){ref-type="supplementary-material"}A), in which the open reading frame (ORF) next to *RRD1* is disrupted; likely, *imp2′Δ* impairs *RRD1* expression and, thus, PP2A-like functionality. This is consistent with the high similarity of *rrd1Δ* and *imp2′Δ* interaction profiles (R = 0.69; data not shown). We also identified deletions in the genes encoding Bck2, involved in protein kinase C signaling ([@bib48]); Rrm3, a replicative DNA helicase targeted by the Mec1-Rad53 pathway ([@bib71], [@bib87]); Rnh201, a ribonuclease H2 involved in Okazaki fragment processing ([@bib67]); and phosphatases Ptp2 and Pph3 ([@bib27], [@bib62]). We compared the interactomes of *irc21Δ* and other PP2A and PP2A-like deletion mutants by calculating the pairwise interactome correlation scores and performed hierarchical clustering of R values ([Figure 3](#fig3){ref-type="fig"}B). The analysis revealed two clusters, the first containing *pph21Δ*, *ppm1Δ*, and *rrd2Δ* (loosely associated with *rts1Δ*) and the second containing *irc21Δ*, *rrd1Δ*, and *tip41Δ* (loosely associated with *sap155Δ*). These observations suggest that *irc21Δ* affects PP2A and PP2A-like phosphatase activities ([Figure 3](#fig3){ref-type="fig"}E). The signatures of genetic interactions shared between *irc21Δ* and either *rrd1Δ* or *tip41Δ* ([@bib14]; [Figure 3](#fig3){ref-type="fig"}C) showed that common interactors were associated with PP2A/PP2A-like regulated processes, including mitosis, checkpoint recovery and adaptation, and mitochondrial maintenance. Other PP2A mutant strains, including *sap185Δ*, *rrd2Δ*, *rts1Δ*, *pph21Δ*, and *pph22Δ*, shared interactions with the *irc21Δ*/*rrd1Δ*/*tip41Δ* signatures to varying degrees ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Irc21 Interacts with PP2A and PP2A-like Phosphatases(A) Comparison of the interactome of the *irc21Δ* array strain with the interactomes of 3,884 mutant array strains by calculating the correlation (R) value of their interaction scores with the 1,712 query mutants (datasets from [@bib14]).(B) Heatmap representing pairwise interactome correlation values of mutants with altered PP2A activity.(C) Heatmap representing SGA interaction scores between query mutants of the *irc21Δ* and *rrd1Δ* and *tip41Δ* signature (rows) and PP2A-related array mutants (columns). Gray fields indicate that the interaction score has not been determined.(D) Genetic interactions of *IRC21* with PP2A components and regulators assessed by SGA screening. Left: quantitative effect of PP2A component deletions (rows) on the growth of *irc21Δ* mutants versus the WT. Right: summary of the confirmation of individual genetic interactions. SS, synthetic sick; SL, synthetic lethal. Interactions with *ppm1* and *tor1* were confirmed by gene targeting.(E) Representation of PP2A and PP2A-like complex subunits and regulators (see text). The blue and orange dotted lines indicate *irc21Δ* mutant genetic interactors found in [@bib14] and in the present study, respectively.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

We conducted an independent SGA analysis mating the *irc21Δ* query strain to the haploid deletion library containing deletions of ∼4,700 non-essential genes ([Figure 3](#fig3){ref-type="fig"}D; [@bib85]). We found 42 negative and 12 positive interactions, causing, respectively, synthetic growth defects or suppression of the mild slow growth phenotype of *irc21Δ* mutants ([Figure S2](#mmc1){ref-type="supplementary-material"}B). In addition, we identified five high-confidence epistatic interactors of *IRC21* by filtering potential epistatic interactors from our dataset, with the positive *IRC21* interactors previously reported in a genome-wide, high-throughput screen ([@bib14]; [Figure S3](#mmc1){ref-type="supplementary-material"}A).

Several PP2A/PP2A-like components displayed negative interactions with *irc21Δ* (significance, *ptc1Δ* and *rts1Δ*; trend, *tip41Δ*, *ppm1Δ*, *rrd1Δ*, and *rrd2Δ*) ([Figures 3](#fig3){ref-type="fig"}D and 3E). We confirmed some of these interactions by random spore analysis and/or tetrad dissection ([Figures 3](#fig3){ref-type="fig"}D, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C). The largest categories of *irc21Δ* negative genetic interactors were metabolic (oxidative stress, TCA cycle, and lipids), and chromatin/checkpoint pathways, which were related to PP2A. In accordance with previous observations ([Figure 2](#fig2){ref-type="fig"}D; cerulenin sensitivity assay), *irc21Δ* displayed negative genetic interaction with *FEN1* deletion ([Figure S2](#mmc1){ref-type="supplementary-material"}B), encoding the fatty acid elongase required for ceramide biosynthesis ([@bib63]); moreover, ceramide hydroxylase Scs7, which contains a cytochrome b~5~ domain like Irc21 ([@bib58]), was identified among the top five high-confidence Irc21 epistatic interactors ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Rescuing interactors ([Figure S2](#mmc1){ref-type="supplementary-material"}B) were involved in phospholipid (*PGC1*), sterol (*NSG2*), and respiratory (*RGI2*, *TRX3*) metabolism, mitochondrial localization/inheritance (*JSN1*), cell morphology (*MGA1*, *DFG5*), nuclear membrane (*MLP2*), and genome integrity (*RAD51*). Epistatic interactors ([Figure S3](#mmc1){ref-type="supplementary-material"}A) were involved in spindle and organelle positioning (*DYN3*, *NIP100*), mitochondrial localization/inheritance (*MMR1*), and ion transport (*PMR1*).

Overall, the *IRC21* interactome analysis supports a function for Irc21 in mitochondrial and lipid metabolism and in influencing PP2A activity, nuclear morphology, and genome integrity.

Irc21 Is Involved in the TORC1-PP2A Regulatory Axis {#sec2.4}
---------------------------------------------------

We next characterized the role of Irc21 in regulating PP2A/PP2A-like activities, which are negatively regulated by the TORC1 pathway ([@bib17]). We found that *tor1Δ* and *tco89Δ*, defective in TORC1 components, were positive interactors of *irc21Δ* ([Figures 3](#fig3){ref-type="fig"}C and 3D). TORC1 controls Tap42 and Sch9 through phosphorylation ([@bib88]; [Figure 4](#fig4){ref-type="fig"}A). Sch9 influences translation initiation and G0 events. Tap42 regulates PP2A and PP2A-like phosphatases, which control the phosphorylation state of Msn2/Msn4, involved in stress response; Rtg1/3, implicated in the retrograde pathway; and Npr1 and Gln3, connected with amino acid synthesis and nitrogen assimilation ([@bib34]).Figure 4Irc21 Inhibits DDR through PP2A Activation(A) Cells were treated with 200 ng/mL rapamycin. Left: band-shift assays following phosphorylation of the PP2A branch proteins Gln3, Nnk1, Npr1, and Rtg3 after 30 min of rapamycin treatment. A horizontal line has been overlaid to assist in determining mobility shifts. Right: band-shift assays following the phosphorylation of Sch9 after 2 hr of rapamycin treatment.(B) WT and *irc21Δ* cells were grown on YPD plates with or without rapamycin, metformin, caffeine, and wortmannin (left). All drugs are inhibitors of the Torc1-Tap42 pathway, represented at the right.(C, E, and F) Cells were grown on YPD plates with or without 3 mM HU.(D) Cells were arrested with α-factor and released in YPD with or without 0.2 M HU. Cells were treated for 3 hr and harvested to detect Rad53.(G) Cells were arrested in G~1~ with α-factor and released in YPD with 0.2 M HU. After 3 hr, cells were released into YPD. Samples were collected at the indicated times to detect Rad53.(H) Cells were grown on YPD + HU plates with or without okadaic acid (OA).See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To probe the Tap42/PP2A signaling branch in *irc21Δ* mutants, we selected four PP2A targets that exhibit clear modifications following TORC1 inhibition through rapamycin treatment: Gln3, Nnk1, Npr1, and Rtg3 ([Figure 4](#fig4){ref-type="fig"}A). As expected, rapamycin led to dephosphorylation of the four PP2A targets; in contrast, all four targets remained hyper-phosphorylated in *irc21Δ*, *rrd1Δ*, and *tip41Δ* cells even in the presence of rapamycin ([Figure 4](#fig4){ref-type="fig"}A, left). Thus, Irc21 participates in the activation of PP2A/PP2A-like pathways like Rrd1 and Tip41. To discern whether Irc21 activates PP2A directly or by inhibiting TORC1, we monitored the TORC1-Sch9 branch. Sch9 was normally dephosphorylated after rapamycin treatment in all mutant strains ([Figure 4](#fig4){ref-type="fig"}A, right). Hence, Irc21 is specifically involved in the activation of the PP2A/PP2A-like sub-pathways, which are also regulated by TORC1. Accordingly, *irc21Δ* mutants are resistant to treatment with a variety of TORC1 inhibitors, such as rapamycin, caffeine, metformin, and wortmannin ([Figure 4](#fig4){ref-type="fig"}B), in analogy to certain PP2A mutants ([@bib70]).

PP2A Influences the Checkpoint Response {#sec2.5}
---------------------------------------

The previous observations led us to hypothesize that, similar to Irc21, PP2A and PP2A-like control the Rad53-mediated response to replication stress. Ablation of the PP2A-positive regulators *RRD1* and *TIP41* mimicked *irc21Δ* in suppressing the HU sensitivity of *rad53-D339A*, *rad53-K227A*, *rad53Δ sml1Δ*, and *mec1Δ sml1Δ* mutant alleles ([Figures S4](#mmc1){ref-type="supplementary-material"}A, S4B, [4](#fig4){ref-type="fig"}C, and 4E). Moreover, deletion of either *RRD1* or *TIP41* in a *mec1Δ sml1Δ* background was able to rescue the crippled Rad53 phosphorylation ([Figure 4](#fig4){ref-type="fig"}D), similar to *irc21Δ* ([Figure 1](#fig1){ref-type="fig"}D). *rrd1Δ* and *tip41Δ* also exhibited delayed Rad53 deactivation following recovery from HU, similar to *irc21Δ* mutants (data not shown).

We performed a screen to find spontaneous extragenic suppressors of *mec1-100* ([@bib64]) lethality on HU and identified a mutation in *TAP42. tap42-G360R* rescued the HU sensitivity of *mec1Δ* and *rad53Δ* cells ([Figures 4](#fig4){ref-type="fig"}E and 4F) and abolished the defective Rad53 phosphorylation in HU-treated *mec1Δ sml1Δ* cells, mimicking the phenotype of *irc21Δ*, *rrd1Δ*, and *tip41Δ* ([Figure 4](#fig4){ref-type="fig"}G).

A gain-of-function mutation could account for the above results. To test whether the mutation caused a constitutive inhibition of PP2A, we analyzed the rapamycin and metformin sensitivity of *tap42-G360R* cells. As expected, and similar to *irc21Δ*, *rrd1Δ*, and *tip41Δ*, *tap42-G360R* mutants were partially resistant to both drugs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Second, after rapamycin treatment, *tap42-G360R* cells showed defective Gln3, Nnk1, and Npr1 dephosphorylation ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Hence, the hyperactive Tap42 allele resembles the absence of PP2A activators.

Because PP2A appeared to target Rad53, we predicted that chemical compounds acting on PP2A activity should also affect *rad53* HU sensitivity. Low doses of okadaic acid (OA) cause selective inhibition of PP2A ([@bib93]) and partially rescued the HU sensitivity *of rad53-K227A* mutants ([Figure 4](#fig4){ref-type="fig"}H).

Irc21 and PP2A Metabolic Signatures {#sec2.6}
-----------------------------------

To characterize the relationship between PP2A and Irc21, we compared the global mass spectrometry metabolic profile of WT, *irc21Δ*, and *rrd1Δ* cells during logarithmic growth in rich medium. Unsupervised clustering by metabolite fold changes clearly grouped the replicates of *irc21Δ* and *rrd1Δ* by genotype but also revealed a degree of similarity between both mutants ([Figure 5](#fig5){ref-type="fig"}A). Of a total of 484 examined compounds, 172 and 111 were significantly changed in *irc21Δ* and *rrd1Δ* cells, respectively (linear model for microarray data \[LIMMA\], p~adj~ = 0.05) ([Figure 5](#fig5){ref-type="fig"}B). The two mutants shared a significant amount of metabolite alterations (79, p = 5 × 10^−11^). Importantly, nearly all of these were co-regulations (72 of 79), suggesting that these 72 alterations define a metabolic, shared Irc21-PP2A signature ([Figure 5](#fig5){ref-type="fig"}B). As expected for low PP2A activity ([@bib78]), the PP2A signature was characterized by a reduction of amino acid biosynthesis intermediates and dipeptides ([Figure 5](#fig5){ref-type="fig"}C, top). It also featured elevated levels of multiple lipids and lipid intermediates (long chain fatty acids, sterol biosynthesis intermediates, lyso-phospholipids, carnitine conjugates, sphingolipid precursors) and a shifted composition of phospholipids to a shorter fatty acid chain length (less than C18). Low PP2A activity correlated with high N-acetylglucosamine (GlcNAc) biosynthesis intermediates, high deoxy-nucleosides (but normal deoxy-nucleotides), and high levels of the methyl donor S-adenosyl-methionine (SAM).Figure 5Irc21 Exerts PP2A-Dependent and PP2A-Activating Metabolic Regulations(A) Unsupervised hierarchical clustering of *irc21Δ* and *rrd1Δ* mutants (six replicates each) based on metabolome alterations during logarithmic growth in rich medium.(B) Summary of metabolome alterations of *irc21Δ* and *rrd1Δ* mutants during logarithmic growth in rich medium. Left: scatterplot of quantitative alterations of individual metabolites in *irc21Δ* and *rrd1Δ* mutants compared with a congenic WT identifies *irc21Δ*-specific (blue), *rrd1Δ*-specific (yellow), common (green, PP2A signature), and opposite (red) regulations. Right: Venn diagram representation of the intersection of metabolic alterations in *irc21Δ* and *rrd1Δ* mutants and intersection significance p value determined by chi-square test.(C) Heatmap representation of altered metabolites by signature. Top: PP2A signature (common alterations in *irc21Δ* and *rrd1Δ*). Bottom: specific regulations in *irc21Δ* and opposite regulations in *irc21Δ* and *rrd1Δ*. As indicated, metabolites were grouped by class.(D) 3-keto-sphinganine, sphinganine, sphinganine-1p, and dihydroceramide were quantified in WT and *irc21Δ* cells. Average values are shown, and error bars represent SEM.(E) Simplified scheme representing ceramide biosynthesis in *S. cerevisiae*. Colored metabolites indicate an increase (red) or a decrease (green) of their amount in *irc21Δ* cells.(F) WT and *irc21Δ* cells were grown on YPD plates with or without myriocin.(G) WT and *irc21Δ* cells were grown on YPD plates with or without syringomycin E.(H) WT and *irc21Δ* cells were grown in SD medium with or without Fumonisin B1.(I) Cells were grown on YPD + HU with or without ceramide.(J) Cells were arrested in G~1~ with α-factor and released in YPD with or without 0.2 M HU, 15 μM ceramide, or 0.2 M HU in combination with 15 μM ceramide for 3 hr.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The metabolite alterations in *irc21Δ* that are not shared by *rrd1Δ* represent PP2A-independent functions of Irc21. We found that several metabolites related to CBR function were altered in *irc21Δ* cells. Accumulation of trichloroacetic acid (TCA) cycle intermediates (aconitate, α-ketoglutarate, fumarate, and malate) and a reduction in the late glycolysis intermediates and acetyl coenzyme A (Ac-CoA) were indicative of altered mitochondrial activity ([Figures 2](#fig2){ref-type="fig"}A and [5](#fig5){ref-type="fig"}C, bottom). The levels of several amino acids derived from glycolysis (Gly and Val) and TCA (Gln, Thr, and Lys) and their derivatives were reduced, whereas urea cycle products accumulated (ornithine, urea). Purine and pyrimidine ribonucleosides and ribonucleotides as well as cytidine triphosphate (CTP)-dependent phospholipid precursors were also reduced, whereas the nucleotide synthesis substrate phosphoribosyl pyrophosphate (PRPP) increased. Cytb5 is also involved in fatty acid metabolism ([Figure 2](#fig2){ref-type="fig"}A), and we found that although fatty acid accumulation was common to *irc21Δ* and *rrd1Δ*, VLCFAs, which are used in the synthesis of ceramides, accumulated in *irc21Δ* cells. Accumulation of VLCFAs and the genetic interaction with the VLCFA synthesis enzyme *FEN1* suggest that *irc21Δ* mutants inefficiently condense sphingolipids and VLCFAs into ceramides and, thus, fail to promote PP2A activation.

We performed a quantitative mass spectrometry analysis of ceramides and related lipid metabolites in WT and *irc21Δ* cells. DHC was more abundant than phytoceramides (PHCs) in WT cells (0.35 pmol/mg and 0.01 pmol/mg, respectively) ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Deletion of *IRC21* reduced the level of DHC ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}A--S5C), whereas the DHC precursors 3-ketodihydrosphingosine (3-keto-DHS), dihydrosphingosine (DHS), dihydrosphingosine-1-P (DHS-1-P), and VLCFA-CoA increased in *irc21Δ* cells ([Figures 5](#fig5){ref-type="fig"}C, 5D, and [S5](#mmc1){ref-type="supplementary-material"}A--S5C). These observations confirmed that *IRC21* deletion impairs ceramide biosynthesis and that the defective step corresponds to the DHS-DHC conversion ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}C). Accordingly, *irc21Δ* mutants were resistant to myriocin ([Figure 5](#fig5){ref-type="fig"}F), an inhibitor of ceramide synthesis acting on serine palmitoyltransferase (SPT), the first enzyme in the sphingolipid biosynthesis pathway ([Figure S5](#mmc1){ref-type="supplementary-material"}C; [@bib33]). Moreover, *irc21Δ* cells were resistant to syringomycin E (SRE) ([Figure 5](#fig5){ref-type="fig"}G; [@bib82]), supporting a defect in sphingolipid biosynthesis ([@bib79]). Addition of exogenous DHC restored *irc21Δ* sensitivity to SRE ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Fumonisin B1, a ceramide synthase inhibitor, pheno-copies *irc21Δ* mutants by causing an increase in DHS and PHS levels and a concomitant decrease in ceramide and, therefore, DHC ([@bib92]). *irc21Δ* mutants were resistant to fumonisin B1 ([Figure 5](#fig5){ref-type="fig"}H). This is consistent with the idea that the drug targets a pathway compromised in *irc21Δ* cells. We conclude that Irc21 promotes the condensation reaction leading to the formation of DHC.

Ceramides, SAM-Mediated Methylation, and TORC1 Inhibition Attenuate the Checkpoint Response by Promoting PP2A Activation {#sec2.7}
------------------------------------------------------------------------------------------------------------------------

We investigated the possibility to abrogate *irc21Δ* HU resistance and PP2A inactivity phenotypes by exogenously providing ceramide. It is known that the cell-permeable ceramide analog C~2~-ceramide induces a dose-dependent activation of PP2A in yeast ([@bib61]). We first analyzed the effect of exogenous ceramide on the rescue of *rad53-K227A* HU sensitivity by *irc21Δ*, *rrd1Δ*, and *tip41Δ*. The sphingolipid suppressed the HU resistance of all mutants ([Figure 5](#fig5){ref-type="fig"}I). We then asked whether ceramide was also able to suppress the *IRC21Δ*-dependent rescue of Rad53 phosphorylation in *mec1Δ* cells. Ceramide-mediated PP2A activation abolished Rad53 phosphorylation, specifically in *irc21Δ mec1Δ* cells, and reduced it in WT and *irc21Δ* cells ([Figure 5](#fig5){ref-type="fig"}J). In addition, ceramide caused Rad53 dephosphorylation during recovery from HU treatment in *irc21Δ mec1Δ* mutants ([Figure S5](#mmc1){ref-type="supplementary-material"}E).

Sur2 and Scs7 are both required for ceramide hydroxylation and are members of the cytochrome b~5~-dependent enzyme family ([Figure S5](#mmc1){ref-type="supplementary-material"}C; [@bib29]). Scs7p contains a cytochrome b~5~-like domain, whereas cytochrome b~5~ may function to transfer electrons to Sur2. Both *SCS7* and *SUR2* deletions partially rescued *mec1Δ sml1Δ* HU sensitivities ([Figures 6](#fig6){ref-type="fig"}A). Thus, defective cytochrome b~5~-dependent enzymes, involved in ceramide biosynthesis, have beneficial consequences for checkpoint mutants exposed to replication stress.Figure 6Ceramides, TORC1, Irc21, and Ppm1 Affect the HU-Induced DDR by Modulating PP2A Activity(A and D) Cells were grown on YPD ± HU.(B) Cells were grown on YPD. 1:10 dilutions were used to highlight growth rate differences.(C) WT and *irc21Δ* cells were grown on YPD plates with or without ethionine or cycloleucine.(E) Cells were arrested with α-factor and released into YPD containing 0.2 M HU alone or in combination with rapamycin (200 ng/mL), ceramide (15 μM), or rapamycin (200 ng/mL) + ceramide (15 μM). Cells were treated for 1 hr and harvested after 5 and 60 min to detect Nnk1 and Rad53.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

SAM levels are critical for methylation and activation of PP2A; in this process, Ppm1 methylates the C terminus of the PP2A catalytic subunit ([@bib81]). Accordingly, *PPM1* ablation partially impaired dephosphorylation of PP2A targets ([Figure S6](#mmc1){ref-type="supplementary-material"}A). We found a negative interaction between *IRC21* and *PPM1* ([Figure 3](#fig3){ref-type="fig"}D) and confirmed that *irc21Δ* and *ppm1Δ* are synthetic sick ([Figure 6](#fig6){ref-type="fig"}B). Moreover, *irc21Δ* and *rrd1Δ* mutants accumulate high levels of SAM ([Figure 5](#fig5){ref-type="fig"}C); accordingly, *irc21Δ* and *rrd1Δ* mutants were hypersensitive to SAM limitation caused by ethionine (a toxic analog of methionine) or cycloleucine (an inhibitor of methionine adenosyl transferase) ([Figure 6](#fig6){ref-type="fig"}C; data not shown). These results suggest that Irc21 and Ppm1 positively regulate PP2A through different mechanisms. Interestingly, like the deletion of *IRC21*, *PPM1* ablation rescued the HU sensitivity of *mec1Δ sml1Δ* mutants ([Figure 6](#fig6){ref-type="fig"}D) and partially recovered the Rad53-defective phosphorylation in HU-treated *mec1Δ* cells (data not shown).

Both rapamycin and ceramide have been shown to promote PP2A activity ([@bib53], [@bib61]). We tested whether rapamycin and ceramide treatments could modulate the HU-induced DDR response. Cells were released from G~1~ in the presence of HU alone or in combination with rapamycin and ceramide ([Figure 6](#fig6){ref-type="fig"}E). After 5 min, when Rad53 was still unphosphorylated, the concomitant presence of rapamycin and ceramide caused PP2A hyperactivation, as indicated by Nnk1 de-phosphorylation. At 60 min, Rad53 phosphorylation was evident in HU-treated cells, partial in HU + rapamycin and HU + ceramide, and abolished in HU + rapamycin and ceramide. We obtained analogous results by treating exponentially growing cells with HU in combination with rapamycin and/or ceramide ([Figure S6](#mmc1){ref-type="supplementary-material"}B).

Altogether, these observations suggest that TORC1, Irc21, and Ppm1 influence the HU-induced DDR by regulating the activity of PP2A and that ceramide levels as well as SAM levels are crucial for Mec1 and Rad53 activation.

Discussion {#sec3}
==========

Activation of Mec1^ATR^ requires multiple post-translational modifications that integrate chromosomal signals and mechanical stimuli ([@bib3]). Deactivation of Mec1^ATR^ promotes cell-cycle recovery or adaptation ([@bib5]). Fine-tuning of the Mec1^ATR^ cascade prevents the deleterious consequences of unscheduled checkpoint activation ([@bib30]). Mec1 and ATR regulate nuclear and non-nuclear pathways ([@bib31], [@bib45], [@bib57]). In yeast, several phosphatases have been involved in DDR silencing, including PP2C (Ptc2/Ptc3) and PP4 (Pph3-Psy2), required for double-strand break (DSB) recovery, and PP1 (Glc7), which promotes HU recovery ([@bib7], [@bib40], [@bib51], [@bib62]). PP2A has been genetically linked to the *RAD53*-*MEC1* pathway but ruled out as one of the main phosphatases implicated in checkpoint control ([@bib36]). PP2A shows activity toward γH2AX, ATM, p53, Chk1, and Chk2 ([@bib11], [@bib18], [@bib26]). Here we demonstrate that PP2A inactivation is beneficial when the Mec1-Rad53 axis is defective. Moreover, PP2A/PP2A-like act in a network with Irc21 and TORC1 to integrate metabolic signals with phosphorylation and dephosphorylation events outside and inside the nucleus and to attenuate the Mec1^ATR^ cascade in cells experiencing replication stress.

*IRC21* ablation rescues *mec1Δ*, *rad53Δ*, and *chk1Δ* sensitivity to HU and promotes HU-induced Rad53 phosphorylation when Mec1 is absent through a process mediated by Tel1. Irc21 was previously connected to the DDR, but the mechanism remained unclear ([@bib28]).

Irc21 is an uncharacterized protein that consists of a cytochrome b5 domain; in accordance, *irc21Δ* mutants influence the respiration rate and ROS levels, display resistance to mersalyl, and show metabolic alterations related to CBR functions. Interestingly, Irc21 localization is mainly cytoplasmic ([@bib28], [@bib35]), although a fraction has been detected in the nucleus ([@bib28]), in mitochondria and vacuoles (collection of yeast cells and localization patterns \[CYCLoPs\]; [@bib41]). A key question is how Irc21 influences the checkpoint response.

We show that Irc21 positively regulates PP2A/PP2A-like activities. *IRC21* ablation causes resistance to TORC1 inhibitors but does not influence the TORC1-Sch9 axis, suggesting that Irc21 is not likely to act upstream of TORC1. The relationship between PP2A and TORC1 is complex and controversial. TORC1 negatively regulates PP2A/PP2A-like through Tap42 phosphorylation ([@bib17]), whereas PP2A stimulates TORC1 through Npr2 phosphorylation ([@bib47]). *irc21Δ* mutants exhibit a negative genetic interaction with PP2A/PP2A-like activators (Rrd1, Rrd2, Tip41, Saps, and Ppm1) and positive genetic interactions with TORC1 components (Tco89 and Tor1) ([Figure 7](#fig7){ref-type="fig"}). We speculate that *IRC21* ablation ameliorates TORC1-defective mutants by limiting PP2A/PP2A-like activities.Figure 7Model: PP2A Links the DRR with Cell MetabolismPP2A and PP2A-like phosphatases are regulated by TORC1 (nitrogen availability), Snf1^AMPK^ (carbon availability), ceramide (sphingolipids and fatty acid availability), and SAM (methionine availability). The two PP2A complexes integrate the metabolic input with the control of DDR. Irc21 acts upstream of PP2A: it shares the PP2A signature but also displays specific metabolic functions (Irc21 signature).

We propose that Irc21 stimulates PP2A and, therefore, attenuates the DDR. Indeed, genetic and pharmacological inactivation of PP2A ameliorates the defective response to replication stress of checkpoint mutants. In addition, exogenous ceramide causes Rad53 dephosphorylation during recovery from HU treatment in *mec1Δ irc21Δ sml1Δ* mutants and abolishes *irc21* rescue of Rad53 phosphorylation in *mec1Δ irc21Δ sml1Δ* cells during HU treatment.

The next key question is how Irc21 regulates PP2A activity. Among all metabolic alterations in *irc21* mutants, elevated ROS are potential contributors to PP2A suppression; ROS accumulation causes PP2A inactivation ([@bib59]). We excluded this hypothesis because ROS scavengers did not affect the capability of *irc21Δ* to rescue the HU sensitivity of checkpoint mutants (data not shown).

*IRC21* ablation alters sphingolipid metabolism and exhibits a reduction in DHC levels and an accumulation of DHC precursors (3-keto-DHS, DHS, DHS-1-P, and VLCFA-CoA). Hence, *irc21Δ* mutants are deficient in ceramide biosynthesis, and the defective step corresponds to the DHS-DHC conversion. DHC is produced by the condensation of DHS with VLCFAs, catalyzed by ceramide synthases (Lag1, Lac1, Lip1). The reverse reaction, hydrolysis of ceramides into sphingosine and fatty acid, is catalyzed by Ydc1 and Ypc1 ceramidases. A synthesis defect or elevated ceramidase activity would cause accumulation of DHS and a reduction in DHC, as we can observe in the absence of Irc21 ([@bib56]). Accordingly, *irc21Δ* mutants are resistant to fumonisin B1, a ceramide synthase inhibitor ([@bib92]). Hence, we favor the hypothesis that Irc21 promotes the condensation reaction leading to the formation of DHC. One possibility is that Irc21 facilitates the activity of the ceramide synthase; intriguingly, *LAC1* transcription is regulated by Rox1, a heme-dependent anaerobic repressor ([@bib42]). Another possibility is that Irc21 counteracts the activity of the Ydc1 and Ypc1 ceramidases that hydrolyze ceramides into sphingosine and fatty acid. Notably, Ydc1 or Ypc1 overexpression phenocopies the DHS accumulation and DHC reduction observed in *irc21* mutants ([@bib55], [@bib56]). Interestingly, Irc21 binds cardiolipin (CL), a mitochondrial phospholipid ([@bib24]) that is known to activate ceramidases ([@bib20]).

Similar to *irc21Δ*, ablation of *SUR2* and *SCS7*, two other members of the cytochrome b~5~-dependent enzyme family involved in the hydroxylation of sphingolipid long-chain bases and ceramides ([@bib29]), ameliorates the replication stress sensitivity of checkpoint mutants. Intriguingly, we identified *SCS7* as an epistatic interactor of *IRC21.* It is unlikely that this interaction reflects a role of Irc21 in ceramide hydroxylation because a hydroxylation defect would likely not lead to diminished DHC levels. Together, these observations suggest that both ceramide synthesis and hydroxylation are required for efficient PP2A-mediated checkpoint control.

Ceramides activate PP2A in yeast and mammals ([@bib61]). Hence, Irc21 might directly stimulate PP2A and attenuate the DDR by contributing to the production of ceramides. Interestingly, rapamycin and ceramide treatments cause a synergistic stimulation of PP2A activity, consistent with the view that TORC1 and Irc21 regulate PP2A activity in a negative and positive way, respectively ([Figure 7](#fig7){ref-type="fig"}).

PP2A activity is stimulated by the SAM-Ppm1 axis ([@bib47]). The synthetic sickness between *ppm1* and *irc21* mutants may therefore result from the simultaneous ablation of two independent positive regulatory pathways leading to PP2A activation ([Figure 7](#fig7){ref-type="fig"}). In this scenario, the low PP2A activity observed in *ppm1* mutants would depend on the lack of PP2A methylation, whereas, in *irc21* mutants, it may result from limiting ceramide levels. Intriguingly, we show that *irc21* mutants display elevated SAM levels, raising the possibility that Ppm1-mediated PP2A methylation may facilitate basal PP2A activity in the absence of ceramide-dependent PP2A activation; consistently, *irc21* mutants are particularly sensitive to treatments that limit SAM availability.

We propose that the DDR is attenuated by PP2A/PP2A-like, which are negatively regulated by the TORC1-Tap42 axis and positively regulated by the Irc21-ceramide and SAM-Ppm1 pathways ([Figure 7](#fig7){ref-type="fig"}).

Nutrients not only supply energy and building blocks for cellular growth but also exert crucial regulatory functions. PP2A controls the phosphorylation status of several targets involved both in cell metabolism and the DDR. It integrates signals from nitrogen and carbon metabolism as a central TORC1 effector ([@bib34], [@bib68]), methionine metabolism by a methylation event that is sensitive to the levels of *S*-adenosylmethionine ([@bib81]), and sphingolipid metabolism as ceramide-activated phosphatase ([@bib38], [@bib61]). Here we show that nutritional pathways impinge on the DDR by regulating PP2A, demonstrating a key role of PP2A in transducing metabolic signals to checkpoint kinases.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti Rad53 (clone EL7) (Dilution for western blot 1:5)In house ([@bib22])N/ARabbit polyclonal anti Mre11 (clone 263) (Dilution for western blot 1:15000)In house ([@bib37])N/ARabbit polyclonal anti Histone H2A phospho S129 (Dilution for western blot 1:500)AbcamCat\# ab15083; RRID: [AB_301630](nif-antibody:AB_301630){#intref0010}Rabbit polyclonal anti Histone H2A (Dilution for western blot 1:3500)Active MotifCat\# 39235Mouse monoclonal anti c-MYC (clone 9E10) (Dilution for western blot 1:2000)Santa Cruz BiotechnologyCat\# sc-40, RRID: [AB_627268](nif-antibody:AB_627268){#intref0015}Mouse monoclonal anti-Viral V5-TAG (Clone SV5-Pk1) (Dilution for western blot 1:30000)Bio-RadCat\# MCA1360G, RRID: [AB_1172162](nif-antibody:AB_1172162){#intref0020}Goat Anti-Mouse IgG (H + L)-HRP Conjugate (Dilution for western blot 1:15000)Bio-RadCat\# 1706516Goat Anti-Rabbit IgG (H + L)-HRP Conjugate (Dilution for western blot 1:15000)Bio-RadCat\# 1706515**Chemicals, Peptides, and Recombinant Proteins**HydroxyureaSigmaCat\# H8627RapamycinSigmaCat\# R0395MetforminSigmaCat\# D150959CaffeineSigmaCat\# C8960WortmanninSigmaCat\# W1628Okadayc acidLC laboratoriesCat\# O-2220C~2~ ceramideSigmaCat\# A7191Dihydroceramide C~2~SigmaCat\# C7980MyriocinSigmaCat\# M1177Paraquat dichloride hydrateSigmaCat\# 36541MersalylSigmaCat\# M9784Tert-butyl hydroperoxideAldrichCat\# 416665Terbinafine hydrochlorideSigmaCat\# T8826FluonazoleSigmaCat\# F8929CeruleninSigmaCat\# C2389Syringomycin ELaboratory of Jon TakemotoN/AFumonisin B1EnzoCat\# BML-SL220L-EthionineSigmaCat\# E1260CycloleucineAldrichCat\# A48105**Deposited Data**Raw data: MetabolomicsThis study; Mendeley data<http://dx.doi.org/10.17632/jfhwwhczx8.1>Raw data: Synthetic Genetic Array (SGA)This study; Mendeley data<http://dx.doi.org/10.17632/jfhwwhczx8.1>**Experimental Models: Organisms/Strains**All *Saccharomyces cerevisiae* yeast strains used in this study were W303 derivatives with the wild type *RAD5* locus. They are listed in [Table S1](#mmc2){ref-type="supplementary-material"}.This studyN/A*MATa* deletion mutant array (S288C)OpenBiosystemsCat\#: YSC1053*MATα* query strain (S288C). See [Table S1](#mmc2){ref-type="supplementary-material"}.Laboratory of Charles BooneN/A**Oligonucleotides**See [Table S2](#mmc3){ref-type="supplementary-material"} for a list of oligonucleotides used in this study.This studyN/A**Software and Algorithms**MultiExperimentViewer 4.9.0 (MeV)[@bib73]<https://sourceforge.net/projects/mev-tm4/>LIMMA (MeV module)[@bib76]<https://sourceforge.net/projects/mev-tm4/>RStudio 1.0.136[@bib72]<https://www.rstudio.com/products/rstudio/download2/>pheatmap 1.0.8 (R package)[@bib43]<https://CRAN.R-project.org/package=pheatmap>HT Colony Grid Analyzer 1.1.7[@bib13]<https://sourceforge.net/projects/ht-col-measurer/>

Contact for Reagents and Resource Sharing {#sec4.2}
-----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marco Foiani (<marco.foiani@ifom.eu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Yeast Strains {#sec4.3.1}

All yeast strains used in this study are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. All strains and genetic manipulations were verified by polymerase chain reaction (PCR) and phenotype. Gene deletions were carried out using either tetrad dissection or standard PCR-based strategies to amplify resistance cassettes with appropriate flanking sequences, and replacing the target gene by homologous recombination. Carboxy-terminal tags were similarly made with the PCR-based method to amplify resistance cassettes with flanking sequences. Primer sequences for gene deletions/carboxy-terminal tags and disruption/alteration controls are listed in the [Key Resources Table](#sec4.1){ref-type="sec"} or available upon request, respectively.

Method Details {#sec4.4}
--------------

### Media and drug sensitivity assay {#sec4.4.1}

Unless otherwise stated, yeast strains were grown in yeast extract/peptone with 2% glucose (YPD). YPD agar plates were supplemented with adenine. Cells were synchronized in G1 with α-factor to a final concentration of 3 μg/ml. For drug sensitivity assay, cells were grown overnight. Serial 1:5 dilutions of stationary cultures were made and one drop of each dilution was pin-spotted onto agar plates, containing drugs. Plates were incubated for 2-3 days at 28°C.

For liquid drug sensitivity assay, yeast strains were grown in SD liquid medium at the initial concentration of 10^5^ cell/ml in microtiter wells. Cultures were either left untreated (control-solvent) or were treated with the drug of interest. The absorbance (OD~595~) of untreated and treated cultures was measured after 12-18 hr. 3 independent repeats were performed. For ceramide experiments, we noticed a rapid response (few minutes for PP2A activity, within one hour for DDR activity).

### Synthetic Genetic Array Screening {#sec4.4.2}

Synthetic genetic array (SGA) was carried out as described ([@bib85], [@bib86]). Shortly, congenic *irc21*Δ (6 replicates) and wt (4 replicates) query strains were crossed with the haploid viable library ([@bib85]). Colony sizes were quantified with the Colony Grid Analyzer (version 1.1.7) ([@bib13]), and normalized to the intra-dish 80-percentile. A 1 x standard error separation of normalized wt and *irc21*Δ colony sizes was used to call candidate hits for negative interactions. A 10% increase of *irc21*Δ colony sizes in relation to the *irc21*Δ 80-percentile and the respective normalized wt colony size, and a 1 x standard error separation from the *irc21*Δ 80-percentile were used to call candidates for rescue interactions.

### Tetrad dissection and random spore analysis {#sec4.4.3}

Standard procedures were used for tetrad dissection and random spore analysis ([@bib1], [@bib84]). Mata and Matα cells were mixed on rich medium and allowed to mate at 28°C. Sporulation was induced at 23°C by transfer to VB sporulation medium. Ascal walls were removed by digestion with zymolase at 37°C. The four spores of each tetrad were separated from each other, germinated on YPD, and allowed to grow before scoring for genetic markers. For random spore analysis, a small amount of spores was inoculated in water and plated on marker selection plates.

### Western Blotting {#sec4.4.4}

Protein extracts for western blotting were prepared following cell fixation using trichloroacetic acid and analyzed by SDS-polyacrylamide gel electrophoresis. Briefly, cells were quickly spun down and the pellet was resuspended in 20% TCA and lysed by bead beating. Lysate and precipitate/debris was mixed with 200 μL 5% TCA and pelleted. The pellet was resuspended in 100 μL Laemli buffer 1X (β-mercaptoethanol as reducing agent*)* and 100 μL Tris base 1M, boiled for 5 min. After centrifugation, the supernatant was transferred in new tubes.

Antibodies used for detection are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Detection was done through electrogenerated chemiluminescence (ECL, GE- Healthcare).

### Fluorescence-activated cell sorting (FACS) analysis {#sec4.4.5}

Cell cycle analysis was conducted as previously described ([@bib65]).

Cells were spun down and the pellet was resuspended in 250mM Tris-HCl pH 7.5, 70% ethanol and kept on ice for at least 30 min. The pellet was resuspended in 50mM Tris-HCl pH 7.5 and RNase A 1mg/ml and incubated at 37°C. The pellet was resuspended in 200mM TRIS-HCl pH 7.5, 200mM NaCl, 78mM MgCl2, Propidium Iodide. Before cytofluorimetric analysis, cells were diluted in Tris-HCl pH 7.5 in tubes and sonicated.

### Budding index analysis {#sec4.4.6}

After sonication, cells were fixed by the addition of 3.7% formaldehyde and 0.9% NaCl. Cells were examined under a light microscope, by counting 200 cells per time point.

### Measurement of intracellular ROS {#sec4.4.7}

ROS measurement was conducted as previously described ([@bib69]). Shortly, exponentially growing cells were harvested and resuspended in PBS containing the oxidant-sensitive probe 2′,7′-dichlorofluorescin diacetate (DCFH-DA). Cells were broken with glass beads and fluorescence was measured with excitation and emission wavelengths of 485 and 528 nm, respectively.

### Measurement of oxygen consumption {#sec4.4.8}

Respiration of log-phase *S. cerevisiae* cells was measured by polarographic analysis using a Clark's type oxygen electrode (Hansatech Instrument Ltd, Pentney UK) according to standard procedures, upon addition of dinitrophenol as uncoupling agent of respiration/ATP synthesis.

### Search for suppressors of mec1-100 sensitivity to HU {#sec4.4.9}

To search for suppressor mutations of the HU-sensitivity of *mec1-100* mutant, 1x10^6^ *mec1-100* cells were plated on YEPD in the presence of 25mM HU. Survivors were crossed to wt cells to identify by tetrad analysis that the suppression events were due to single-gene mutations. Subsequent genetic analyses allowed grouping the single-gene suppression events in 4 classes. The class that showed the most efficient suppression was chosen and the mutations altering open reading frames within the reference *S. cerevisiae* genome were identified by next-generation Illumina sequencing (IGA technology services). To confirm that the *tap42-G360R* mutation was responsible for the suppression, a *URA3* gene was integrated downstream of the *tap42-G360R* stop codon and the resulting strain was crossed to wt cells to verify by tetrad dissection that the suppression of the *mec1-100* HU sensitivity co-segregated with the *URA3* allele.

### Metabolic analysis {#sec4.4.10}

Yeast cells were grown to logarithmic phase (1x10^7^ cells/mL) in YPD medium in 6 replicates. 5x10^8^ cells per replicate were harvested by centrifugation, washed in water, snap-frozen in liquid nitrogen and stored at −80°C. Metabolite extraction and Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy analysis of 484 metabolites were performed by Metabolon (Durham, North Carolina) as previously described ([@bib10]). Missing metabolite raw intensity values were filled in with the lowest detectable intensity of the respective metabolite, and all raw intensities were normalized to the median intensity of the respective replicate. Fold changes and significant alterations were calculated with the LIMMA method implemented in MultiExperiment Viewer (MeV) software (version 4.9.0) ([@bib73], [@bib76]) using an adjusted *p* value of 0.05 and a minimum fold-change of 1.3.

### TrueMass Ceramide Panel {#sec4.4.11}

Metabolites were isolated from cell pellets by sequential chloroform/methanol extraction and aqueous potassium chloride liquid-liquid extraction. The chloroform/methanol solution contained internal standards (Cer12:0, Cer19:0, dhCer12:0, hexCer12:0, \[Avanti Polar Lipids, Alabaster, AL\]) The organic layer was evaporated in a stream of nitrogen, reconstituted and subjected to a solid phase extraction clean up step on silica \[Si, 100 mg, Supelco, Bellefonte, PA\]. The ceramide fraction was eluted, evaporated in a stream of nitrogen, reconstituted and an aliquot was injected onto an AB Sciex 4000 QTRAP (Sciex, Foster City, CA)/Acquity (Waters, Milford, MA) LC-MS/MS system equipped with a reversed phase UHPLC column \[Zorbax Eclipse Plus C8, 2.1 × 150 mm, 1.8 μm, Agilent Technologies\] using a gradient of 2mM ammonium formate/0.2% formic acid in water and 1 mM ammonium formate/0.2% formic acid in Acetonitrile:Isopropanol (60:40). The mass spectrometer was operated in MRM mode using positive electrospray ionization.

The peak areas of the analyte fragment ions were measured against the peak area of the respective fragment ions of the corresponding internal standards. For the purposes of this panel, the fragment ion m/z 264 was used for ceramides with a sphingosine backbone and the m/z 266 fragment was used for analytes with a sphinganine backbone. Quantitation was based on a series of five calibration standard samples that were included in each run. Calibration standards contained 26 reference compounds. For analytes for which calibration standards were not commercially available, a surrogate analyte from the same compound class was used for quantitation (e.g., quantitation of CER 22:1 is based on CER 20:0 calibration standards). A total of 56 analytes covering ceramides, dihydroceramides, hexosylceramides and lactosylceramides with different fatty acid composition (14:0, 16:0, 18:0, 18:1, 20:0, 20:1, 22:0, 22:1, 24:0, 24:1, 26:0, 26:1) were determined.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Interactome correlation analysis {#sec4.5.1}

Interactome correlation analysis of *irc21*Δ was performed with published genome-wide SGA scores ([@bib14]). The genetic interaction scores between 3884 array and 1712 query strains were used to calculate correlation coefficients (R) of the query strain *irc21*Δ with all other query strains, using the CORREL function in Microsoft Excel 2013 ([Figure 3](#fig3){ref-type="fig"}A). The pairwise correlation coefficients (R) between PP2A subunits were calculated accordingly ([Figure 3](#fig3){ref-type="fig"}B). Genetic interactions underlying the interactome similarity between *irc21Δ*, *rrd1Δ* and *tip41Δ* were derived from the intermediate cutoff interactor table in ([@bib14]; [Figure 3](#fig3){ref-type="fig"}C). Interactors were included if either *rrd1Δ* or *tip41Δ* showed the same interaction type as *irc21Δ*. Unsupervised hierarchical clustering and heatmap representation of correlation coefficients and genetic interaction scores were done in MeV.

### Metabolome Analysis {#sec4.5.2}

Unsupervised hierarchical clustering of metabolome samples by Pearson correlation coefficient and heatmap representation were performed in R using the pheatmap library (version 1.0.8). Significance analysis was performed with LIMMA implemented in MeV as described above. Significances of the intersections of metabolite alterations were calculated by chi-square test. Heatmaps for visualization of altered metabolite classes were generated with MeV.

### Statistical tests {#sec4.5.3}

The statistical significance was assessed using the indicated assays. Student's t test was used for pairwise comparisons. ANOVA was used for comparisons of multiple groups. Number of replicates (n) and p values are specified in corresponding Figure legends.

Data and Software Availability {#sec4.6}
------------------------------

Raw data have been deposited to Mendeley Data and are available at <http://dx.doi.org/10.17632/jfhwwhczx8.1>.
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